For healthcare professionals only


NICE calls for more research on ELISA tests for Crohn’s disease

BMJ 2016; 352 doi: (Published 18 February 2016) Cite this as: BMJ 2016;352:i1019
  1. Jacqui Wise
  1. London

Enzyme linked immunosorbent assay (ELISA) kits show real promise in guiding treatment for people with Crohn’s disease, but the National Institute for Health and Care Excellence (NICE) warns that evidence is insufficient to recommend their routine use in the NHS.1

Tumour necrosis factor alpha (TNF-α) inhibitors, such as infliximab and adalimumab, help to stop inflammatory responses in the gut that are characteristic of Crohn’s disease. Although TNF-α inhibitors can help many people with Crohn’s, some do …

View Full Text

Log in

Log in through your institution


* For online subscription